Investigational drug · Phase 2
AMT-143
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Bunionectomy, Bunion.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AMT-143"
First trial start
2026
Nov 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AMT-143", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bunionectomy
- Bunion
Largest trials
Live from ClinicalTrials.gov: studies naming "AMT-143" as an intervention, largest first.
AmacaThera Inc.Industry
NCT07858734 · 60 participants (planned) · Start Nov 1, 2026 · Primary completion Apr 15, 2027
Drug: AMT-143; AMT-143 · For: Bunionectomy; Bunion
Sites: Sherbrooke, Canada
AmacaThera Inc.Industry
NCT06709612 · 0 participants · Start Jan 27, 2025 · Primary completion Mar 2026
Drug: AMT-143; ropivacaine · For: Hernia Repair; Hernia Inguinal; Hernia Surgery and 2 more
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Bunionectomy
- GRT7040Phase 21 trial
Grünenthal GmbH · Acute Pain, Bunionectomy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.